This industry has a long tradition of softening the truth about what leadership failure actually costs. But if we look closely, we would realize that life sciences is a tournament, somewhat analogous to the NCAA’s March Madness. Out of every 10,000 potential drug compounds screened in preclinical research, only one will eventually receive FDA approval. An analysis in Clinical and Translational Science is even more sobering, placing the true number closer to one in 20,000 to 30,000 compounds.
The attrition continues relentlessly at every single stage:
- Phase I Transition: Of the candidates that survive preclinical work and enter Phase I, the 2014 to 2023 cohort from Norstella and Citeline shows only a 47 percent advance rate to Phase II. That rate is falling—down from over 75 percent between 2006 and 2008 and dropping 40 percent below in the most recent years.
- The Valley of Death: Phase II remains the ultimate proving ground, with advancement to Phase III hovering around 28 to 30 percent.
- Late-Stage Execution: Phase III to regulatory filing runs around 58 percent, while filing to final approval reaches approximately 89 percent.
- Cumulative Probability: When the full chain is compounded from Phase I onward, the cumulative likelihood of approval is a staggering 6.7 to 7.9 percent.
- Commercial Reality: Among the small fraction of approved drugs that reach commercial launch, roughly half still fail to recover their overall development costs.
By any honest metric, biopharma operates as a failure-dominated industry. Yet, most companies do not fail simply because the underlying biology was wrong. They fail at the critical translation points between stages, where scientific reality must be converted into capital structures, deal terms, and governance decisions. The companies that survive each milestone do not do so out of luck; they survive because their leadership possesses the Dual Fluency required to translate scientific progress into sound financial and strategic execution, which we can learn from Dual Fluency: How Life Sciences Leaders Master the Language of Science and Capital by David H. Crean, Ph.D.
This book explores why scientific excellence alone is not enough to build successful life sciences companies. The book introduces the concept of Dual Fluency, the ability for leaders to operate effectively in both the language of science and the language of capital, enabling them to translate discoveries into investment opportunities, strategic partnerships, and sustainable organizations. Drawing from decades of experience in life sciences transactions, advisory work, and leadership, Crean explains how companies succeed or fail at three critical translation points: Data to Capital, where scientific evidence becomes an investment thesis; Discovery to Deal, where innovation becomes strategic value; and Bench to Boardroom, where scientific insight and financial judgment guide leadership decisions. Through practical frameworks, real world examples, and leadership lessons, the book provides founders, executives, investors, and board members with the tools needed to navigate uncertainty, allocate resources wisely, and move transformative therapies from discovery to patients